[go: up one dir, main page]

AR112828A1 - Proceso para la preparación de 7-(4,7-diazaespiro[2.5]octan-7-il)-2-(2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4-ona - Google Patents

Proceso para la preparación de 7-(4,7-diazaespiro[2.5]octan-7-il)-2-(2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4-ona

Info

Publication number
AR112828A1
AR112828A1 ARP180102704A ARP180102704A AR112828A1 AR 112828 A1 AR112828 A1 AR 112828A1 AR P180102704 A ARP180102704 A AR P180102704A AR P180102704 A ARP180102704 A AR P180102704A AR 112828 A1 AR112828 A1 AR 112828A1
Authority
AR
Argentina
Prior art keywords
compound
formula
preparation
dimethylimidazo
octan
Prior art date
Application number
ARP180102704A
Other languages
English (en)
Inventor
Christian Moessner
Christophe Pfleger
Gerard Moine
Fabienne Hoffmann-Emery
Daniel Vincent Fishlock
Serena Maria Fantasia
Jean-Michel Adam
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR112828A1 publication Critical patent/AR112828A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
    • B01J23/44—Palladium
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/70—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of the iron group metals or copper
    • B01J23/74—Iron group metals
    • B01J23/755—Nickel
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Catalysts (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

Abstract

La presente solicitud se refiere a un proceso para la preparación de derivados de 7-(4,7-diazaespiro[2,5]octan-7-il)-2-(2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4-ona útiles como compuestos farmacéuticamente activos. Reivindicación 1: Un proceso para la preparación de un compuesto de fórmula (1) o la sal de HCl del mismo, que comprende hacer reaccionar un compuesto de fórmula (2) con un ácido fuerte, en particular HCl. Reivindicación 15: Un compuesto de fórmula (2). Reivindicación 16: Un compuesto de fórmula (3), en la que X es un sulfonato de alquilo o arilo (tal como pTolSO₃-, CH₃SO₃-, fenil-SO₃), sulfonatos de alquilo o arilo fluorados (tal como CF₃SO₃-, nonaflato), o un haluro (tal como Cl, Br o I). Reivindicación 17: Un compuesto de fórmula (4).
ARP180102704A 2017-09-22 2018-09-21 Proceso para la preparación de 7-(4,7-diazaespiro[2.5]octan-7-il)-2-(2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4-ona AR112828A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17192711 2017-09-22

Publications (1)

Publication Number Publication Date
AR112828A1 true AR112828A1 (es) 2019-12-18

Family

ID=59955477

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180102704A AR112828A1 (es) 2017-09-22 2018-09-21 Proceso para la preparación de 7-(4,7-diazaespiro[2.5]octan-7-il)-2-(2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4-ona

Country Status (14)

Country Link
US (3) US11390632B2 (es)
EP (2) EP3684766B1 (es)
JP (2) JP7075484B2 (es)
KR (2) KR102691657B1 (es)
CN (2) CN116813648A (es)
AR (1) AR112828A1 (es)
AU (1) AU2018337597B2 (es)
CA (1) CA3075968C (es)
HR (1) HRP20251594T1 (es)
IL (1) IL273268B2 (es)
MX (1) MX2020002711A (es)
SG (1) SG11202002610TA (es)
TW (1) TWI812646B (es)
WO (1) WO2019057740A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102691657B1 (ko) * 2017-09-22 2024-08-05 에프. 호프만-라 로슈 아게 7-(4,7-다이아자스피로[2.5]옥탄-7-일)-2-(2,8-다이메틸이미다조[1,2-b]피리다진-6-일)피리도[1,2-a]피리미딘-4-온 유도체의 제조 방법
KR20240135889A (ko) 2018-10-19 2024-09-12 에프. 호프만-라 로슈 아게 피리도[1,2-a]피리미딘-4-온 유도체의 형태, 그의 제형 및 그의 제조 방법
EP4004003A1 (en) 2019-07-31 2022-06-01 Teva Pharmaceuticals International GmbH Solid state forms of risdiplam and process for preparation thereof
WO2022048675A1 (zh) * 2020-09-07 2022-03-10 苏州科睿思制药有限公司 Risdiplam晶型及其制备方法和用途
WO2022162107A1 (en) 2021-02-01 2022-08-04 Sandoz Ag Crystalline form of risdiplam
EP4308576B1 (en) 2021-03-17 2025-04-23 F. Hoffmann-La Roche AG New thiazolopyrimidinone derivatives
EP4308577B1 (en) 2021-03-17 2024-12-25 F. Hoffmann-La Roche AG New thiadiazolopyrimidone derivatives
JP2024509995A (ja) 2021-03-18 2024-03-05 エフ． ホフマン－ラ ロシュ アーゲー リスジプラムを調製するための方法
JP2025508110A (ja) 2022-03-10 2025-03-21 エフ． ホフマン－ラ ロシュ アーゲー ピリド［１，２－ａ］ピリミジン－４－オン誘導体
WO2024003798A1 (en) * 2022-06-29 2024-01-04 Biophore India Pharmaceuticals Pvt. Ltd. A novel process for the preparation of 7 (4, 7- diazaspiro [2.5] octan-7-yl)-2-(2,8 dimethylimidazo[1,2-b] pyrid azin-6- yl) pyrido-4h-[1,2-a] pyrimidin-4-one with novel intermediates
WO2024069646A1 (en) * 2022-09-26 2024-04-04 Natco Pharma Limited Improved process for the preparation of risdiplam and its intermediates
EP4669647A1 (en) * 2023-01-21 2025-12-31 Harman Finochem Limited METHOD FOR PREPARING RISDIPLATIN, NEW INTERMEDIARIES AND THEIR METHOD FOR PREPARATION
CN121219298A (zh) 2023-04-20 2025-12-26 豪夫迈·罗氏有限公司 噻吩并[3,2-b]吡啶衍生物
CN121399140A (zh) * 2023-05-13 2026-01-23 哈曼菲诺化学有限公司 新型的利司扑兰晶型及其制备方法
CN117050096A (zh) * 2023-07-17 2023-11-14 杭州诺澳生物医药科技有限公司 一种利司扑兰的制备方法
CN116947865B (zh) * 2023-08-11 2025-06-13 扬州联澳生物医药有限公司 一种利司扑兰中间体的合成方法和利司扑兰中间体
WO2025057179A1 (en) * 2023-09-12 2025-03-20 Harman Finochem Limited A process for purification of risdiplam

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA029984B1 (ru) 2011-12-30 2018-06-29 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Соединения для лечения спинальной мышечной атрофии
SG11201404713PA (en) 2012-02-10 2014-09-26 Ptc Therapeutics Inc Compounds for treating spinal muscular atrophy
US10882868B2 (en) 2014-05-15 2021-01-05 Hoffmann-La Roche Inc. Compounds for treating spinal muscular atrophy
CR20160518A (es) 2014-05-15 2017-02-21 Hoffmann La Roche Compuestos para tratar atrofia muscular espinal
CN105111201B (zh) * 2014-10-16 2017-01-11 上海页岩科技有限公司 5-甲基-2-(吡啶-2-基氨基)-8H-吡啶并[2,3-d]嘧啶-7-酮化合物
EP4360707A3 (en) * 2015-11-12 2024-08-07 F. Hoffmann-La Roche AG Compositions for treating spinal muscular atrophy
AR106652A1 (es) * 2015-11-12 2018-02-07 Hoffmann La Roche Compuestos para tratar la esclerosis lateral amiotrófica
KR102691657B1 (ko) * 2017-09-22 2024-08-05 에프. 호프만-라 로슈 아게 7-(4,7-다이아자스피로[2.5]옥탄-7-일)-2-(2,8-다이메틸이미다조[1,2-b]피리다진-6-일)피리도[1,2-a]피리미딘-4-온 유도체의 제조 방법

Also Published As

Publication number Publication date
US12122791B2 (en) 2024-10-22
US11390632B2 (en) 2022-07-19
AU2018337597A1 (en) 2020-03-26
US20200216472A1 (en) 2020-07-09
CN111132981B (zh) 2023-10-31
BR112020005549A2 (pt) 2020-10-06
SG11202002610TA (en) 2020-04-29
EP3684766C0 (en) 2025-10-29
JP2020534330A (ja) 2020-11-26
EP3684766A1 (en) 2020-07-29
CA3075968A1 (en) 2019-03-28
US20220324881A1 (en) 2022-10-13
KR102691657B1 (ko) 2024-08-05
IL273268A (en) 2020-04-30
JP7075484B2 (ja) 2022-05-25
KR20230020580A (ko) 2023-02-10
EP4663641A3 (en) 2026-01-07
WO2019057740A1 (en) 2019-03-28
JP2022107003A (ja) 2022-07-20
EP4663641A2 (en) 2025-12-17
IL273268B1 (en) 2023-01-01
MX2020002711A (es) 2020-07-20
IL273268B2 (en) 2023-05-01
AU2018337597B2 (en) 2021-03-25
EP3684766B1 (en) 2025-10-29
CN111132981A (zh) 2020-05-08
CA3075968C (en) 2023-04-04
HRP20251594T1 (hr) 2026-01-30
JP7398510B2 (ja) 2023-12-14
US20250084102A1 (en) 2025-03-13
KR20200058468A (ko) 2020-05-27
TW201920205A (zh) 2019-06-01
TWI812646B (zh) 2023-08-21
CN116813648A (zh) 2023-09-29

Similar Documents

Publication Publication Date Title
AR112828A1 (es) Proceso para la preparación de 7-(4,7-diazaespiro[2.5]octan-7-il)-2-(2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4-ona
MX2021004487A (es) Nuevas formas de derivados de pirido[1,2-a]pirimidin-4-ona, su formulacion y su proceso de elaboracion.
BR112014032338A2 (pt) cristais de sal
AR131260A2 (es) Compuestos para tratar atrofia muscular espinal
TN2019000133A1 (en) PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF
AU2014270524A8 (en) 2-phenylimidazo [1,2-a]pyrimidines as imaging agents
HRP20231276T1 (hr) Inhibitor egfr-a za liječenje raka
UY35935A (es) Compuestos de nicotinamida sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4
EA201170771A1 (ru) Органические соединения
PE20171104A1 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
PE20160026A1 (es) Compuestos heterociclicos como agentes para control de plagas
WO2014128545A3 (en) An improved process for the preparation of dolutegravir
JP2013529196A5 (es)
PE20190339A1 (es) 1h-pirazolo[4,3-b] piridinas como inhibidores de pde1
PE20142366A1 (es) Compuestos triazolo como inhibidores de pde 10
MX2016003422A (es) Imidazo[1,2-a]piridina-7-aminas como herramientas de imagen.
PE20250776A1 (es) Sales y formas solidas de un inhibidor de fgfr y procesos para su preparacion
EA201390644A1 (ru) ГИДРАТ ТАРТРАТА 1-{(2S)-2-АМИНО-4-[2,4-БИС-(ТРИФТОРМЕТИЛ)-5,8-ДИГИДРОПИРИДО[3,4-d]ПИРИМИДИН-7(6H)-ИЛ]-4-ОКСОБУТИЛ}-5,5-ДИФТОРПИПЕРИДИН-2-ОНА
PE20160125A1 (es) Pirazolpiridinas sustituidas
PL3083627T3 (pl) Pochodne [l,2,4]triazolo[l,5-a]pyrimidyny jako inhibitory proteasomu pierwotniaka do leczenia chorób pasożytnych, takich jak leiszmanioza
PE20181447A1 (es) Derivados de eter ciclico de pirazolo[1,5-a]pirimidin-3-carboxiamida
AR125144A1 (es) Nuevo proceso
NZ744341A (en) Process for preparing 7h-pyrrolo [2, 3-d] pyrimidine compounds
AR100648A1 (es) Proceso de preparación de azd5363 y compuesto
RU2011108627A (ru) ИНГИБИТОР PIM1-КИНАЗЫ, 6-[(4-МЕТИЛ-L-1-ПИПЕРАЗИНИЛ)МЕТИЛ]-ИНДОЛО[1',7':1,2,3]ПИРРОЛО[3',4':6,7]АЗЕПИНО[4,5-b]ИНДОЛ-1,3(2Н,10Н)-ДИОН, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ